Bell’s Palsy Market Performance in 15 Major Markets Reviewed by Black Swan Analysis in Its Report Published at MarketPublishers.com

LONDON – Bell's palsy, otherwise known as idiopathic facial paralysis (IFP), attacks nearly 40,000 Americans annually. It afflicts both women and men of all ages, but it is not widespread before the age of 15 or over the age of 60.  It disproportionately affects diabetic people or those with upper respiratory disorders like a cold or the flu.

In most instances, a Bell's palsy is a one-off event. Around 1 in 14 affected people can have further episodes some time or other in the offing, frequently several years after.

The treatment of the disease is mainly aimed at improving facial/cranial nerve function, decreasing neuronal damage, and preventing complications from corneal exposure.

Treatment encompasses corticosteroid therapy, antiviral agents, and eye care. Surgical treatment modes comprise facial nerve decompression, implantable devices put into the eyelid, facial nerve grafting, tarsorrhaphy, and direct brow lift, among others.

New report “Epiomic Epidemiology Series: Bell's Palsy Forecast in 15 Major Markets 2017-2027” drawn up by Black Swan Analysis canvasses the present-day incident population for Bell's palsy across 15 leading country markets, dissected by gender and 5-year age group. It provides current incidence rates, presents an all-round overview of the disease risk factors, diagnosis and prognosis as well as specific variations by ethnicity and geographic region/country. 

The research study casts light on some of the key symptoms and co-morbidities of IFP and also provides the overall incidence rates. It analyses the sub-populations in IFP country-wise alongside providing detailed 10-year forecasts.

Reasons to Buy:

• Be able to quantify the patient populations in the Bell’s palsy marketplace to target the future product development, launch plans and pricing strategies.
• Gain comprehensive insights into the incidence rates of the subdivided types of IFP, with identification of patient segments with strong potential.
• Get granular, true information on clinical trials across different countries.
• Gain an understanding on the influence from specific comorbidities on IFP incident population.
• Identify sub-populations in Bell’s palsy which need treatment.
• Get wise of the specific markets with the largest number of IFP patients.

More new reports elaborated by Black Swan Analysis are provided at its page. 

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com